ClinicalTrials.gg
RecruitingNCT07218341Updated Nov 4, 2026

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 4 interventional study of Pirtobrutinib and Idelalisib in Chronic Lymphocytic Leukemia and Lymphoma, Small Lymphocytic, sponsored by Eli Lilly and Company. Recruiting at 50 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 4, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
10th of 23
150 · median 87
Started
2026
with 4 others
Phase 4
3 of 23
3 open now
Primary completion
2030-05
later than 13 of 18 live
Registered
20th of 23
by date
Lead sponsor
5 of 23
Eli Lilly and Company

Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 10th largest by planned enrollment, is one of 5 that started in 2026, is one of 3 in phase 4, reaches primary completion later than 13 of the 18 other live ones, and was the 20th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Lymphoma, Small Lymphocytic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion criteria

Exclusion Criteria:

  • This is not applicable to this study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Pirtobrutinib (Arm A)

    Participants receive pirtobrutinib orally

    Drug: Pirtobrutinib

  • Experimental
    Idelalisib (Arm B)

    Participants receive idelalisib orally

    Drug: Idelalisib

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with a Grade 3 or Higher Treatment-emergent Adverse Events (AEs)

    Time frame: Time from First Dose of Study Intervention (Study Day 1) through 30 Days After Last Dose of Study Intervention or Start of New Anticancer Therapy, whichever is Earlier

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as the time from randomization in a randomized originator study, or from the first dose in a non-randomized originator study, until death from any cause

    Time frame: Time from Enrollment in the Originator Study until Death from Any Cause (Up to 93 Months)

07

Study locations

22 of 50 sites recruiting
  • Mitchell Cancer Institute
    Mobile, Alabama 36693, United States
    Recruiting
    • · Contact334-660-5108
    • Anita Mazloom · Principal investigator
  • Arizona Oncology Associates, P.C. - HOPE
    Tucson, Arizona 85711, United States
    Not yet recruiting
    • · Contact520-886-0206
    • Sudhir Manda · Principal investigator
  • Cancer Specialists, LLC
    Jacksonville, Florida 32256, United States
    Recruiting
    • · Contact904-538-4488
    • Ayed Ayed · Principal investigator
  • Minnesota Oncology Hematology, P.A.
    Coon Rapids, Minnesota 55433, United States
    Recruiting
    • · Contact612-884-6300
    • Avina Singh · Principal investigator
  • Cayuga Cancer Center
    Ithaca, New York 14850, United States
    Not yet recruiting
    • Cynthia Davis · Principal investigator
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
    New York, New York 10065-6007, United States
    Recruiting
    • · Contact646-608-4273
    • Prioty Islam · Principal investigator
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45211, United States
    Recruiting
    • · Contact513-751-2273
    • Kruti Patel · Principal investigator
  • Texas Oncology - Paris
    Fort Worth, Texas 76104, United States
    Recruiting
    • · Contact214-370-1000
    • Harris Naina · Principal investigator
  • US Oncology - Texas Oncology
    Kyle, Texas 78640, United States
    Recruiting
    • · Contact210-595-5300
    • David Friedman · Principal investigator
  • The Alfred Hospital
    Melbourne, 3004, Australia
    Recruiting
    • · Contact61396561111
    • Constantine Tam · Principal investigator
  • LKH - Universitätsklinikum der PMU Salzburg
    Salzburg, 5020, Austria
    Not yet recruiting
    • · Contact+435725525822
    • Alexander Egle · Principal investigator
  • AZ Delta
    Roeselare, 8800, Belgium
    Not yet recruiting
    • · Contact+3251237322
    • Lien Deleu · Principal investigator
  • Princess Margaret Cancer Centre - University Health Network
    Toronto, M5G 2M9, Canada
    Not yet recruiting
    • · Contact4169462827
    • Christine Chen · Principal investigator
  • Xuanwu Hospital Capital Medical University
    Beijing, 100053, China
    Not yet recruiting
    • · Contact+8613691066953
    • Wuhan Hui · Principal investigator
  • Hunan Cancer Hospital
    Changsha, 410013, China
    Not yet recruiting
    • Hui Zhou · Principal investigator
  • Sun Yat-sen University Cancer Center
    Guangdong, 510060, China
    Recruiting
    • · Contact+8613798032244
    • He Huang · Principal investigator
  • Nanfang Hospital of Southern Medical University
    Guangzhou, 510515, China
    Recruiting
    • · Contact+8613725119762
    • RU FENG · Principal investigator
  • Gansu Provincial Cancer Hospital
    Lanzhou, 730050, China
    Not yet recruiting
    • · Contact+8613519607327
    • Jie Cui · Principal investigator
  • The First Affiliated Hospital of Nanchang University
    Nanchang, 330006, China
    Recruiting
    • · Contact+86079188693682
    • Fei Li · Principal investigator
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
    Not yet recruiting
    • · Contact+862164175590
    • Junning Cao · Principal investigator
  • Taizhou Hospital of Zhejiang Province
    Taizhou, 317000, China
    Recruiting
    • · Contact+8613515861286
    • Qunyi Guo · Principal investigator
  • Hematology Hospital of the Chinese Academy of Medical Sciences
    Tianjin, 300020, China
    Recruiting
    • · Contact+8622023909015
    • Rui Lv · Principal investigator
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, 300060, China
    Recruiting
    • · Contact+8618622221227
    • Lihua Qiu · Principal investigator
  • Affiliated Cancer Hospital of Xinjiang Medical University
    Ürümqi, 830000, China
    Not yet recruiting
    • · Contact+869917968088
    • Shune Yang · Principal investigator
  • The Affiliated Hospital of Xuzhou Medical College
    Xuzhou, 221000, China
    Recruiting
    • · Contact+86516085802297
    • Jiang Cao · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, 450003, China
    Not yet recruiting
    • · Contact+864000371818
    • Keshu Zhou · Principal investigator
  • University Hospital Center Zagreb
    Zagreb, 10000, Croatia
    Not yet recruiting
    • · Contact+38512388675
    • Igor Aurer · Principal investigator
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 500 05, Czechia
    Not yet recruiting
    • · Contact+420495834851
    • Martin Simkovic · Principal investigator
  • Centre Henri Becquerel
    Rouen, 76038, France
    Not yet recruiting
    • · Contact+33232082223
    • Stephane Lepretre · Principal investigator
  • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
    Budapest, 1097, Hungary
    Not yet recruiting
    • · Contact+3614558217
    • Zoltan Matrai · Principal investigator
  • Debreceni Egyetem
    Debrecen, 4032, Hungary
    Not yet recruiting
    • · Contact+3652255196
    • Arpad Illes · Principal investigator
  • St. James's Hospital
    Dublin, D08 NHY1, Ireland
    Not yet recruiting
    • · Contact+353868703651
    • Carmel Waldron · Principal investigator
  • Beaumont Hospital
    Dublin, DUBLIN 9, Ireland
    Not yet recruiting
    • · Contact+35318092010
    • Philip Murphy · Principal investigator
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
    Not yet recruiting
    • · Contact97236973576
    • Yair Herishanu · Principal investigator
  • Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo
    Alessandria, 15121, Italy
    Not yet recruiting
    • · Contact+390131207825
    • Gioacchino Catania · Principal investigator
  • Azienda Ospedaliera Universitaria Careggi
    Florence, 50134, Italy
    Recruiting
    • · Contact+39557947958
    • alessandro sanna · Principal investigator
  • Presidio Ospedaliero Papardo
    Messina, 98158, Italy
    Not yet recruiting
    • · Contact+39903992246
    • Donato Mannina · Principal investigator
  • Fondazione IRCCS San Gerardo dei Tintori
    Monza, 20900, Italy
    Not yet recruiting
    • · Contact+390392331
    • Carlo Gambacorti-Passerini · Principal investigator
  • Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
    Perugia, 06129, Italy
    Not yet recruiting
    • · Contact+39755783990
    • PAOLO SPORTOLETTI · Principal investigator
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Rome, 00138, Italy
    Recruiting
    • · Contact+390630156016
    • LUCA LAURENTI · Principal investigator
  • Azienda Ospedaliera S. Maria Di Terni
    Terni, 05100, Italy
    Not yet recruiting
    • · Contact+39744205971
    • Arcangelo Liso · Principal investigator
  • Tokai University Hospital
    Isehara, 259-1193, Japan
    Recruiting
    • · Contact81120023812
    • Yoshiaki Ogawa · Principal investigator
  • Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza
    Brzozów, 36-200, Poland
    Not yet recruiting
    • · Contact+48134309728
    • Jacek Krzanowski · Principal investigator
  • Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
    Not yet recruiting
    • · Contact+48795149026
    • Marta Sobas · Principal investigator
  • Pratia Onkologia Katowice
    Katowice, 40-519, Poland
    Recruiting
    • · Contact+48600388282
    • Sebastian Grosicki · Principal investigator
  • Hospital Universitario Marques De Valdecilla
    Santander, 39008, Spain
    Not yet recruiting
    • · Contact+34942202520
    • LUCRECIA YANEZ SAN SEGUNDO · Principal investigator
  • Hospital Universitario Virgen Del Rocio
    Seville, 41010, Spain
    Not yet recruiting
    • · Contact+34955013277
    • Fatima de la Cruz Vicente · Principal investigator
  • Castle Hill Hospital
    Hull, HU16 5JQ, United Kingdom
    Recruiting
    • · Contact+441482461296
    • David Allsup · Principal investigator
  • St James's University Hospital
    Leeds, LS9 7TF, United Kingdom
    Recruiting
    • · Contact+441132433144
    • Talha Munir · Principal investigator
  • GenesisCare
    Newmarket, CB8 7XN, United Kingdom
    Recruiting
    • · Contact+44 1223 816789
    • George Follows · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2030, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2025
First posted
Oct 20, 2025
StartActual
Mar 9, 2026
Primary completionEst.
May 2030
CompletionEst.
Dec 2032
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites changed recruiting status (14 now recruiting)
Show 14 sites
  • Oncology Hematology Care Inc · Cincinnati, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Paris · Fort Worth, United StatesNot yet recruiting→Recruiting
  • US Oncology - Texas Oncology · Kyle, United StatesNot yet recruiting→Recruiting
  • The Alfred Hospital · Melbourne, AustraliaNot yet recruiting→Recruiting
  • Sun Yat-sen University Cancer Center · Guangdong, ChinaNot yet recruiting→Recruiting
  • The First Affiliated Hospital of Nanchang University · Nanchang, ChinaNot yet recruiting→Recruiting
  • Taizhou Hospital of Zhejiang Province · Taizhou, ChinaNot yet recruiting→Recruiting
  • Tianjin Medical University Cancer Institute & Hospital · Tianjin, ChinaNot yet recruiting→Recruiting
  • The Affiliated Hospital of Xuzhou Medical College · Xuzhou, ChinaNot yet recruiting→Recruiting
  • Azienda Ospedaliera Universitaria Careggi · Florence, ItalyNot yet recruiting→Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, ItalyNot yet recruiting→Recruiting
  • Pratia Onkologia Katowice · Katowice, PolandNot yet recruiting→Recruiting
  • Castle Hill Hospital · Hull, United KingdomNot yet recruiting→Recruiting
  • GenesisCare · Newmarket, United KingdomNot yet recruiting→Recruiting
Nov 4, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Debreceni Egyetem · Debrecen, HungaryContact person changed (no phone or email listed)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    14 sites changed recruiting status (14 now recruiting)
    Show 14 sites
    • Oncology Hematology Care Inc · Cincinnati, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Paris · Fort Worth, United StatesNot yet recruiting→Recruiting
    • US Oncology - Texas Oncology · Kyle, United StatesNot yet recruiting→Recruiting
    • The Alfred Hospital · Melbourne, AustraliaNot yet recruiting→Recruiting
    • Sun Yat-sen University Cancer Center · Guangdong, ChinaNot yet recruiting→Recruiting
    • The First Affiliated Hospital of Nanchang University · Nanchang, ChinaNot yet recruiting→Recruiting
    • Taizhou Hospital of Zhejiang Province · Taizhou, ChinaNot yet recruiting→Recruiting
    • Tianjin Medical University Cancer Institute & Hospital · Tianjin, ChinaNot yet recruiting→Recruiting
    • The Affiliated Hospital of Xuzhou Medical College · Xuzhou, ChinaNot yet recruiting→Recruiting
    • Azienda Ospedaliera Universitaria Careggi · Florence, ItalyNot yet recruiting→Recruiting
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, ItalyNot yet recruiting→Recruiting
    • Pratia Onkologia Katowice · Katowice, PolandNot yet recruiting→Recruiting
    • Castle Hill Hospital · Hull, United KingdomNot yet recruiting→Recruiting
    • GenesisCare · Newmarket, United KingdomNot yet recruiting→Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Debreceni Egyetem · Debrecen, HungaryContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07218341
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Mar 9, 2026
Primary completion
May 2030 (estimated)
Completion
Dec 2032 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pirtobrutinib · Idelalisib

Start the discussion